cytochrome P450 family 27 subfamily C member 1Genealiases: []
Q-omics provides the consensus-scored CYP27C1 profile across patient tissues and cancer cell-line models. CYP27C1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CYP27C1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CYP27C1 RNA expression shows 16,779 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where CYP27C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP27C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP27C1 survival associations across molecular data types. CYP27C1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP27C1 RNA expression–survival associations across cancer types. High CYP27C1 expression shows unfavorable associations in ACC, PAAD, STAD and KIRC, but favorable associations in UCS and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CYP27C1 RNA expression.
This table summarizes CYP27C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CYP27C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP27C1 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LUAD, LUSC and BLCA. The HNSC box plot shows higher CYP27C1 RNA expression in tumor versus normal tissue (log2 FC = +2.501, t-test p < 0.001).
This table shows molecular features associated with CYP27C1 in patient tissues and cancer cell lines. In patient samples, CYP27C1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP27C1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
